Nanotechnology and Diabetes Management: Recent Advances and Future Perspectives

Rashid, Rumaisa; Naqash, Amreen; Bader, Ghulam Nabi; Sheikh, Faheem A.

doi:10.1007/978-981-15-5622-7_6

Cited by 4 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the most distinctive feature of nano-based drug in diabetes management is early diagnosis, monitoring of disease progression, and introducing antidiabetic agents. In previous researches, different types of biomedical nanoparticles are available and studied for insulin delivery in the treatment of diabetes mellitus including: polymeric biodegradable nanoparticles (nanospheres and nanocapsules), polymeric micelles, ceramic nanoparticles, dendrimers, and liposomes [7] Biocompatible nanoparticles with optimized physical, chemical, and biological properties can overcome the limitations of conventional anti-diabetic drugs [8]. Metal Nanoparticles are highly designed as medicinal agents for the of number of diseases such as cancer, diabetes, Parkinson's, Alzheimer, HIV/AIDS, arthritis, hepatitis, cirrhosis, spinal cord injury tuberculosis and cardio vascular diseases due to their unique physical, chemical and biological properties [9].…”

Section: Introductionmentioning

confidence: 99%

Silver/chitosan/ascorbic acid nanocomposites ameliorate diabetic nephropathy in the model of type 1 diabetes

Mahmoud¹,

Mohamed²,

Fahmy³

et al. 2021

GSC Biol. and Pharm. Sci.

View full text Add to dashboard Cite

Aims: The present study aimed to evaluate anti-diabetic properties of AgNPs/chitosan/ascorbic acid nanocomposites (Ag-NCs) in streptozotocin-induced diabetic rats. Main methods: Eighteen male Wistar albino rats were divided into three main groups (6 rats/group); control, diabetic and Ag-NCs groups. Control group: after a single dose of citrate buffer (0.1 mol/l, i.p), the rats orally received 1 ml distilled water daily for four weeks. The diabetic model was induced by a single dose of streptozotocin (60 mg/kg, i.p) for type 1diabetes. Diabetic groups were treated orally with and Ag-NCs (0.25mg/Kg body weight) daily for four weeks. Key findings: AgNPs/chitosan/ascorbic acid nanocomposite group showed a reduction in the concentrations of glucose, NO, MDA, creatinine, urea and uric acid. At the same time, it appeared a general increase in insulin, CAT, and SOD activities and GSH concentration. The histopathological investigation illustrated a clear improvement in renal architecture. Significance: The suggested mechanism of action for Ag-NCs in decreasing diabetic nephropathy includes two pathways; the hypoglycemic activity and the antioxidant role of Ag-NCs

show abstract

Section: Introductionmentioning

confidence: 99%

Silver/chitosan/ascorbic acid nanocomposites ameliorate diabetic nephropathy in the model of type 1 diabetes

Mahmoud¹,

Mohamed²,

Fahmy³

et al. 2021

GSC Biol. and Pharm. Sci.

View full text Add to dashboard Cite

show abstract

Prevention of Protein Glycation by Nanoparticles: Potential Applications in T2DM and Associated Neurodegenerative Diseases

2022

View full text Add to dashboard Cite

Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review

Lv,

Zhai,

Sun

et al. 2024

J Biol Eng

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a condition that causes swelling of the blood vessels of the retina and leaks blood and fluids. It is the most severe form of diabetic eye disease. It causes vision loss in its advanced stage. Diabetic retinopathy is responsible for causing 26% of blindness. Very insufficient therapies are accessible for the treatment of DR. As compared to the conventional therapies, there should be enhanced research on the controlled release, shorter duration, and cost-effective therapy of diabetic retinopathy. The expansion of advanced nanocarriers-based drug delivery systems has been now employed to exploit as well as regulate the transport of many therapeutic agents to target sites via the increase in penetration or the extension of the duration of contact employing production by enclosing as well as distributing tiny molecules in nanostructured formulation. Various polymers have been utilized for the manufacturing of these nanostructured formulations. Chitosan possesses incredible biological and chemical properties, that have led to its extensive use in pharmaceutical and biomedical applications. Chitosan has been used in many studies because of its enhanced mucoadhesiveness and non-toxicity. Multiple studies have used chitosan as the best candidate for manufacturing nanocarriers and treating diabetic retinopathy. Numerous nanocarriers have been formulated by using chitosan such as nanostructured lipid carriers, solid lipid nanoparticles, liposomes, and dendrimers for treating diabetic retinopathy. This current review elaborates on the recent advancements of chitosan as a promising approach for the manufacturing of nanocarriers that can be used for treating diabetic retinopathy.

show abstract

Nanotechnology and Diabetes Management: Recent Advances and Future Perspectives

Cited by 4 publications

References 46 publications

Silver/chitosan/ascorbic acid nanocomposites ameliorate diabetic nephropathy in the model of type 1 diabetes

Silver/chitosan/ascorbic acid nanocomposites ameliorate diabetic nephropathy in the model of type 1 diabetes

Prevention of Protein Glycation by Nanoparticles: Potential Applications in T2DM and Associated Neurodegenerative Diseases

Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review

Contact Info

Product

Resources

About